RxDoctor Payments Data

Jeffrey Cloud, MD

Gastroenterology · Casper, WYNPI 1518179126

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,610 of the $3,298 with a category attached, or 79.1%. 20 manufacturers reported payments, led by AbbVie at 33.9% of the total.

$3,298in general payments, 2019–2025

Across 137 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Braintree Laboratories, Inc.$646
  • Gilead$356
  • Takeda Pharmaceuticals U.S.A., Inc.$260
  • Sanofi$196
  • Pfizer$145
  • plus $576 from 14 others

What the payments were for

  • Food & beverage$2,61079%
  • Education$562%
  • Gifts$63319%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gastroenterology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$151,315
Medicare patients
548
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$165,869
CreonLipase/Protease/Amylase13$26,104
Dexlansoprazole DrDexlansoprazole40$14,126
LinzessLinaclotide12$6,335
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates65$4,287
SutabSod Sulf/Pot Chloride/Mag Sulf26$4,153
Pantoprazole Sodium218$2,339
Colestipol Hcl24$1,932
LoperamideLoperamide Hcl16$1,495
Omeprazole107$1,366
Budesonide DrBudesonide13$969
CholestyramineCholestyramine (With Sugar)19$933
Esomeprazole Magnesium29$599
Sulfasalazine11$488
Nortriptyline Hcl20$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,119$32,44025 claims
Braintree Laboratories, Inc.Sutab$646$4,15326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gastroenterology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other gastroenterology in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →